Colistin resistance of Acinetobacter baumannii: Clinical reports, mechanisms and antimicrobial strategies

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 7, 2012, Pages 1607-1615

  Cai, Yun ^a   Chai, Dong ^a   Wang, Rui ^a   Liang, Beibei ^a   Bai, Nan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Combination therapy; Heteroresistance; Multidrug resistance

Indexed keywords

AMIKACIN; AZITHROMYCIN; BACTERIAL PROTEIN; COLISTIN; DOXYCYCLINE; FOSFOMYCIN; IMIPENEM; LIPID A; LIPOPOLYSACCHARIDE; MEROPENEM; PHOSPHOETHANOLAMINE; RIFAMPICIN; SULBACTAM; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CREATININE CLEARANCE; DNA SEQUENCE; DRUG BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; REVIEW; STEADY STATE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; ASIA; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EUROPE; HUMANS; PREVALENCE;

EID: 84862677946     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks084     Document Type: Review

References (84)

1. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
2. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010; 35: 219-26.
3. Tasina E, Haidich AB, Kokkali S et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-44.
4. Hornsey M, Ellington MJ, Doumith M et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 1589-93.
5. Dizbay M, Altuncekic A, Sezer BE et al. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008; 32: 29-32.
6. Kulah C, Celebi G, Aktas E et al. Unexpected tigecycline resistance among Acinetobacter baumannii isolates: high minor error rate by Etest. J Chemother 2009; 21: 390-5.
7. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 772-4.
8. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
9. Hancock RE. Peptide antibiotics. Lancet 1997; 349: 418-22.
10. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.
11. Hejnar P, Kolar M, Hajek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of b-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. Acta Univ Palacki Olomuc Fac Med 1999; 142: 73-7.
12. Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-50.
13. Herrera ME, Mobilia LN, Posse GR. Comparative evaluation of the sensitivity of Acinetobacter to colistin, using the prediffusion and minimum inhibitory concentration methods: detection of heteroresistant isolates. Rev Argent Microbiol 2011; 43: 115-9.
14. Rodriguez CH, De Ambrosio A, Bajuk M et al. In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries 2010; 4: 164-7.
15. Rodriguez CH, Bombicino K, Granados G et al. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 2009; 65: 188-91.
16. Yau W, Owen RJ, Poudyal A et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 2009; 58: 138-44.
17. Li J, Rayner CR, Nation RL et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49: 4814-5.
18. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008; 52: 351-2.
19. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183-90.
20. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66: 2070-4.
21. Rolain JM, Roch A, Castanier M et al. Acinetobacter baumannii Resistant to colistin with impaired virulence: a case report from France. J Infect Dis 2011; 204: 1146-7.
22. Lopez-Rojas R, Jimenez-Mejias ME, Lepe JA et al. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis 2011; 204: 1147-8.
23. Gomez-Garces JL, Aracil B, Gil Y et al. Susceptibility of 228 non-fermenting Gram-negative rods to tigecycline and six other antimicrobial drugs. J Chemother 2009; 21: 267-71.
24. Mezzatesta ML, Trovato G, Gona F et al. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann Clin Microbiol Antimicrob 2008; 7: 4.
25. Quinteira S, Grosso F, Ramos H et al. Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. Antimicrob Agents Chemother 2007; 51: 3465-6.
26. Garcia-Penuela E, Aznar E, Alarcon T et al. [Susceptibility pattern of Acinetobacter baumannii clinical isolates in Madrid vs. Hong Kong]. Rev Esp Quimioter 2006; 19: 45-50.
27. Dobrewski R, Savov E, Bernards AT et al. Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital. Clin Microbiol Infect 2006; 12: 1135-7.
28. Arroyo LA, Garcia-Curiel A, Pachon-Ibanez ME et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol 2005; 43: 903-5.
29. Arroyo LA, Mateos I, Gonzalez V et al. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009; 53: 1295-6.
30. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. J Chemother 2011; 23: 13-6.
31. Eser OK, Ergin A, Hascelik G. [Antimicrobial resistance and existence of metallo-b-lactamase in Acinetobacter species isolated from adult patients]. Mikrobiyol Bul 2009; 43: 383-90.
32. Lee YT, Huang LY, Chiang DH et al. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int J Antimicrob Agents 2009; 34: 580-4.
33. Sung H, Choi SJ, Yoo S et al. [In vitro antimicrobial synergy against imipenem-resistant Acinetobacter baumannii]. Korean J Lab Med 2007; 27: 111-7.
34. Chang KC, Lin MF, Lin NT et al. Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan. J Microbiol Immunol Infect 2012; 45: 37-42.
35. Lee SC, Huang SS, See LC et al. In vitro activities of nine current antibiotics against culprit bacteria in nosocomial infections in an institution in northern Taiwan. Chang Gung Med J 2011; 34: 580-9.
36. Ko KS, Suh JY, Kwon KT et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007; 60: 1163-7.
37. Doi Y, Husain S, Potoski BA et al. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009; 15: 980-2.
38. Keen EF III, Robinson BJ, Hospenthal DR et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns 2010; 36: 819-25.
39. Hawley JS, Murray CK, Griffith ME et al. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother 2007; 51: 376-8.
40. Tognim MC, Gales AC, Penteado AP et al. Dissemination of IMP-1 metallo-b-lactamase-producing Acinetobacter species in a Brazilian teaching hospital. Infect Control Hosp Epidemiol 2006; 27: 742-7.
41. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002; 71: 635-700.
42. Adams MD, Nickel GC, Bajaksouzian S et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB twocomponent system. Antimicrob Agents Chemother 2009; 53: 3628-34.
43. Moffatt JH, Harper M, Harrison P et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54: 4971-7.
44. Moffatt JH, Harper M, Adler B et al. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011; 55: 3022-4.
45. Henry R, Vithanage N, Harrison P et al. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-b-1,6-N-acetylglucosamine. Antimicrob Agents Chemother 2012; 56: 59-69.
46. Soon RL, Nation RL, Cockram S et al. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J Antimicrob Chemother 2011; 66: 126-33.
47. Park YK, Choi JY, Shin D et al. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. Int J Antimicrob Agents 2011; 37: 525-30.
48. Beceiro A, Llobet E, Aranda J et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011; 55: 3370-9.
49. Gunn JS. The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol 2008; 16: 284-90.
50. Lim LM, Ly N, Anderson D et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010; 30: 1279-91.
51. Cai Y, Li R, Liang B et al. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 3998-9.
52. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007; 51: 3413-5.
53. Owen RJ, Li J, Nation RL et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59: 473-7.
54. Dudhani RV, Turnidge JD, Nation RL et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65: 1984-90.
55. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6.
56. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
57. Pankuch GA, Lin G, Seifert H et al. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52: 333-6.
58. Principe L, D'Arezzo S, Capone A et al. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 2009; 8: 18.
59. Peck KR, Kim MJ, Choi JY et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii including colistin- or tigecycline-resistant isolates. J Med Microbiol 2012; 61: 353-60.
60. Sheng WH, Wang JT, Li SY et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 2011; 70: 380-6.
61. Timurkaynak F, Can F, Azap OK et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27: 224-8.
62. Fulnecky EJ, Wright D, Scheld WM et al. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect 2005; 51: e249-51.
63. Santimaleeworagun W, Wongpoowarak P, Chayakul P et al. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 2011; 42: 890-900.
64. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 5316-22.
65. Li J, Nation RL, Owen RJ et al. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45: 594-8.
66. Rodríguez-Hernández MJ, Saugar J, Docobo-Pérez F et al. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2006; 58: 95-100.
67. Saugar JM, Rodriguez-Hernandez MJ, de la Torre BG et al. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob Agents Chemother 2006; 50: 1251-6.
68. Vila-Farres X, Garcia de la Maria C, Lopez-Rojas R et al. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect 2011.
69. Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 2011; 55: 3534-7.
70. Shields RK, Kwak EJ, Potoski BA et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 2010; 70: 246-52.
71. Ozbek B, Senturk A. Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii. Chemotherapy 2010; 56: 466-71.
72. Candel FJ, Calvo N, Head J et al. A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects. Rev Esp Quimioter 2010; 23: 103-8.
73. Pongpech P, Amornnopparattanakul S, Panapakdee S et al. Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii. J Med Assoc Thai 2010; 93: 161-71.
74. Pachon-Ibanez ME, Docobo-Perez F, Lopez-Rojas R et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 1165-72.
75. Dizbay M, Tozlu DK, Cirak MY et al. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J Antibiot (Tokyo) 2010; 63: 51-3.
76. Lee CH, Tang YF, Su LH et al. Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia. Microb Drug Resist 2008; 14: 233-7.
77. Song JY, Lee J, Heo JY et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2008; 32: 281-4.
78. Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61: 417-20.
79. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007; 29: 51-5.
80. Biancofiore G, Tascini C, Bisa M et al. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. Minerva Anestesiol 2007; 73: 181-5.
81. Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-8.
82. Petrosillo N, Chinello P, Proietti MF et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005; 11: 682-3.
83. Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54: 1085-91.
84. Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 1998; 41: 494-5.